Delivering affordable, high-quality medicines
Sandoz, the generic pharmaceuticals division of Novartis, is a global industry leader, offering affordable, high-quality medicines. It is the third-largest division of Novartis, representing 15% of the Group’s total net sales.
2012 net sales - USD 8.7 billion
Sandoz develops, produces and markets approximately 1,100 molecules worldwide across all major therapeutic areas, as well as biopharmaceuticals, active substances and intermediates. Sandoz has a global presence in over 140 countries, employs over 25,000 people worldwide and has six development centers and a worldwide network of approximately 45 production sites.
In addition to its retail generics business, Sandoz also operates in anti-infectives, opthalmics, respiratory, dermatology and biopharmaceuticals & oncology injectables businessess, where it has a strong leadership position.
Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your healthcare professional about any medical condition or product.
- Enoxaparin sodium injection (Lovenox®)
- Amoxicillin / clavulanic acid (Augmentin®)
- Valsartan HCT (authorized generic of Novartis’s Diovan HCT®)
- Somatropin (Genotropin®)
- Acetylcysteine (Fluimucil®)
- Fentanyl (Duragesic®)
- Omeprazole (Prilosec®)
- Lactobacillus (Linex®)
- Tacrolimus (Prograf®)
- Atorvastatin (Lipitor®)
- *Product names identified by a "®" are trademarks that are not owned by or licensed to the Novartis Group of companies.